Antidepressant use, age, health linked to abnormal binocular vision

Article

According to research from the University of Waterloo in Canada, abnormal binocular vision dramatically increases with age, but is correlated with a patient’s general health and antidepressant use.

Waterloo, Canada-According to research from the University of Waterloo in Canada, abnormal binocular vision dramatically increases with age, but is correlated with a patient’s general health and antidepressant use. 

The study looked at records from 500 patients, ages 60 and over, who received treatment at the university’s on-campus clinic. Data included age, general and ocular history and symptoms, antidepressant use, smoking habits, refraction, visual acuity, binocular vision and eye movement status for the most recent full oculo-visual assessment, and an assessment from 10 years prior.

The study found that about 27 percent of adults in their 60s have a binocular vision or eye movement disorder, and that number rises to 38 percent for those over age 80. Age and use of antidepressants most commonly predicted binocular vision or eye movement disorders. In addition, about 20 percent of the general population has a binocular vision disorder.

According to the university, “Conditions such as diabetes and thyroid disease are known to cause such problems, but this is the first study to link binocular vision disorders with overall general health. Similarly, other writers have discussed a possible association between certain antidepressant drugs and specific binocular vision disorders, but this is the first study to actually demonstrate a link between antidepressant use and binocular vision and eye movement disorders.

"An association does not establish that one causes the other, but rather that they co-exist," says Susan Leat, BSc, PhD, FAAO, PCOptom, who led the study. "It is possible that the effects of poor vision mean that people are more likely to take anti-depressants or make less healthy lifestyle choices."

Next: Glaucoma drug may reverse obesity-related vision loss

Tracrolimus drops associated with improvement of refractory allergic ocular disease

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
© 2025 MJH Life Sciences

All rights reserved.